

- **BUILDING LINKS BETWEEN EUROPE AND AFRICA IN PERSONALISED MEDICINE**


EU-Africa PerMed project

Joaquin Guinea (INNOVATEC)

EU-Africa PerMed Project Coordinator



EU-Africa PerMed has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 964333



**BUILDING LINKS BETWEEN
EUROPE AND AFRICA IN
PERSONALISED MEDICINE**

EU-AFRICA PERMED: THE PROJECT

- ✓ EU-Africa PerMed project has the final objective of integrating African countries into International Consortium for Personalised Medicine (ICPerMed, www.icpermed.eu) activities, thus contributing to a successful implementation of Personalised Medicine (PM) in the global context.
- ✓ It will foster joint PM projects and programmes between Europe and Africa, as well as strengthening bilateral EU-AU science, technology and innovation (STI) relations in the area of health.
- ✓ The project will run for 4 years, starting the 1st February 2021

WHAT IS PERSONALISED MEDICINE?



ICPerMed



What is Personalised Medicine?

- Why does it happen that a treatment for a certain disease works very well for one person, but poorly or not at all for the next person?
- What does our genetic profile tell us about chances and risks for our health?
- Going even further, how can molecular, clinical or lifestyle data support preventing, diagnosing or treating disease?

These are just some of the questions that personalised medicine tries to find answers for.


As a starting point, the term “personalised medicine” itself needs to be defined as this determines future fields of actions and responsibilities. **The work of ICPerMed is based on the definition of personalised medicine given in the [European Council Conclusion on personalised medicine for patients \(2015/C 421/03\)](#).**

It states “[...] that it is widely understood that **PERSONALISED MEDICINE** refers to a **medical model** using characterisation of individuals’ phenotypes and genotypes (e.g. **molecular profiling, medical imaging, lifestyle data**) for tailoring the right **therapeutic strategy** for the right person at the right time, and/or to determine the **predisposition to disease** and/or to deliver timely and targeted prevention.”

WHAT IS PERSONALISED MEDICINE?



'Personalised Medicine' as an umbrella term



Personalised Medicine as an umbrella term.

(source Benediktsson I, EC 2019) .

Dr Indridi Benediktsson presentation is available at <https://www.eulac-permed.eu/wp-content/uploads/2019/11/EULAC-PerMed-Summer-School-Madrid-Nov-2019-Benediktsson.pdf>

EU-AFRICA PERMED: THE PROJECT OBJECTIVES

- **OBJECTIVE 1:** To identify, contact and engage with relevant health-related organizations in Africa to interact and work with throughout the project, including: Research & Innovation (R&I) performers as well as the health care system, policy makers, funding agencies, private sector, civil society organizations and patients, in order to identify key organizations and actors.
- **OBJECTIVE 2:** To explore and analyse with relevant stakeholder, the potential for and advantages of collaboration in PM between Africa and Europe, identifying areas of mutual interest and added value for both regions and building sustainable links between both regions, as a means to integrate the African continent in the global PM agenda.
- **OBJECTIVE 3:** To foster and facilitate the integration of health research funding and policy organisations from African Union (AU) countries in the ICPeMed consortium, though the participation of representatives of these organizations in workshops, conferences and related events and in ongoing collaborative funding actions such as ERA PerMed.

EU-AFRICA PERMED: THE PROJECT OBJECTIVES

- **OBJECTIVE 4:** To seek synergies and align with activities of ongoing EU-Africa research programmes and other by-regional policy actions, such as the European and Developing Countries Clinical Trials partnerships (EDCTP) and the Africa-Europe Alliance for sustainable investments and jobs, as well as with international research consortiums active in Africa (GACD, GloPID-R, GAVI, IRDiRC, Global Alliance, H3Africa).
- **OBJECTIVE 5:** To carry out capacity building and training activities addressing relevant PM issues for Africa, including the wider adoption of PM standards and taking into account the social, cultural, ethical and legal aspects of the African context.
- **OBJECTIVE 6:** To contribute to raising awareness of PM and the benefits of a closer inter and intra-regional collaboration, in order to advance in the implementation of PM approaches, through the dissemination and communication of the project activities and results and the planification of a long-lasting strategy beyond the duration of the project.

EU-AFRICA PERMed: THE CONSORTIUM



EU-AFRICA PERMed: THE PROJECT PARTNERS

PARTIC. Nº	PARTICIPANT ORGANISATION NAME	COUNTRY	TYPE
1 -Coord.	Sociedad para el Fomento de la Innovación Tecnológica - INNO	Spain	SME
2	Ministero della Salute - It-MoH	Italy	Policy and research funding organization
3	European Clinical Research Infrastructure Network - ECRIN	Europe	Research infrastructure
4	Agence Nationale de la Recherche - ANR	France	Research funding organization
5	Instituto de Salud Carlos III – ISCIII	Spain	Policy, funding and research organization
6	Institut National de la Santé et de la Recherche Médicale - INSERM	France	Research organization
7	Egyptian Center for Innovation & Technology Development- ECITD	Egypt	SME
8	South African Medical Research Council – SAMRC	South Africa	Research funding organization
9	Institut de Recherche en Santé, de Surveillance Epidemiologique et de Formations - IRESSEF	Senegal	Research organization
10	African Population & Health Research Centre -APHRC	Kenya/Senegal	Research organization
11	East, Central, and Southern African Health Community - ECSA-HC	Tanzania	Policy maker
12	National Commission for Science, Technology and Innovation – NACOSTI	Kenya	Policy maker
13	African Union Development Agency - AUDA - NEPAD	Africa	AU public agency and funding organization


EU-AFRICA PERMed: ASSOCIATED PARTNERS

ORGANISATION NAME	COUNTRY
NATIONAL HEALTH RESEARCH AUTHORITY	Zambia
ACADEMY OF SCIENTIFIC RESEARCH AND TECHNOLOGY	Egypt
NATIONAL RESEARCH FUND	Kenya
MINISTRY OF HIGHER EDUCATION AND SCIENTIFIC RESEARCH	Tunisia
MINISTRY OF NATIONAL EDUCATION, VOCATIONAL TRAINING, HIGHER EDUCATION AND SCIENTIFIC RESEARCH	Morocco
CANCER ASSOCIATION OF SOUTH AFRICA	South Africa

EU-AFRICA PERMed: EXTERNAL ADVISORY BOARD

NAME	POSITION/EXPERTISE
Dr. ULRIKE BUßHOFF	Senior scientific officer at the Project Management Agency at German Aerospace Centre (DLR-PT). Former Head of the ICPeMed Secretariat.
Prof. MOSES BOCKARIE	Director of International Cooperation (Africa) and Head of Africa Office of European & Developing Countries Clinical Trials Partnership (EDCTP).
Prof. GODFREY BIEMBA	Director and CEO, National Health Research Authority, Zambia.
Prof. MICHÈLE RAMSAY	Director of the Sydney Brenner Institute for Molecular Bioscience (SBIMB) at the U. of the Witwatersrand, Johannesburg. Member of H3Africa.
Prof. ANGELA BRAND	Founding Director and Full Professor of the Institute for Public Health Genomics (IPHG) at Maastricht University, the Netherlands.

EU-AFRICA PERMed: WORK PACKAGES INTERACTIONS




WORK PACKAGE 2 M1-M14	MAPPING THE HEALTH R&I AND POLICY LANDSCAPE IN AFRICA FOR THE IDENTIFICATION OF KEY STAKEHOLDERS, INITIATIVES AND EXPERTISE RELEVANT TO PM
<u>Objectives</u> <ul style="list-style-type: none"> • To identify and contact the most appropriate stakeholders, initiatives and expertise and determine how they can contribute to the project objectives. • To discuss with relevant stakeholders the main challenges and opportunities of PM in Africa • To engage with key target groups and invite them to participate in project activities. 	
<u>Tasks</u> <ul style="list-style-type: none"> • Bibliometric analysis of recent scientific literature to describe the scientific landscape of Personalised Medicine (PM) in Africa • Reviewing the health R&I policy landscape in African countries • Stakeholder mapping • Organization of the first Stakeholder workshop • Preparation of the policy brief: Challenges for PM medicine in Africa and options for a stronger EU-Africa collaboration in PM 	
<u>Deliverables</u> <ul style="list-style-type: none"> • Report: Mapping the scientific and policy landscape of PM in Africa. • Report: Stakeholder mapping • Stakeholder Workshop report • Policy brief: Challenges for EU-Africa collaboration in PM 	

WORK PACKAGE 3 M10-M48	CROSS BORDER COLLABORATION AND IDENTIFICATIONS OF FUTURE ACTIONS IN PM BETWEEN AFRICA AND EUROPE
<p><u>Objectives</u></p> <ul style="list-style-type: none"> • Explore and analyse the potential and advantages of collaboration of Africa and Europe in the field of PM. • Identify areas of mutual interest and added value for future collaboration. • Build sustainable links between Africa and Europe in PM research, development, innovation and implementation to better integrate the African continent in the global PM agenda. 	
<p><u>Tasks</u></p> <ul style="list-style-type: none"> • Explore and analyse the potential and advantages of collaboration in PM between Africa and Europe • Stakeholder workshop 2: Define collaboration between Africa and Europe in PM • Defining and implementing actions for the future • Stakeholder workshop 3: Sustainability of collaboration and dissemination activities, including research and policy dialogue in PM 	
<p><u>Deliverables</u></p> <ul style="list-style-type: none"> • List of African PM needs • List of areas of mutual interest between Europe and Africa • Report on gaps-and-needs assessment • Action plan to facilitate, foster and promote PM collaboration of Africa and Europe • Policy brief: Sustainable European and African collaboration in Personalised Medicine 	

WORK PACKAGE 4 M7-M48	TRANSLATING SCIENCE TO POLICY - ENHANCING THE DIALOGUE BETWEEN AFRICAN COUNTRIES AND EUROPE IN COLLABORATION WITH ICPERMED AND ERA PERMED
<p><u>Objectives:</u></p> <ul style="list-style-type: none"> • To foster and facilitate the integration of African Union countries in the ICPerMed consortium, • To seek synergies and align with activities of ongoing EU-Africa research programmes and other bi-regional policy actions, such as the EDCTP, and research consortiums such as the GACD. 	
<p><u>Planned activities</u></p> <ol style="list-style-type: none"> 1. Integration of AU countries in the ICPerMed consortium and in ERA PerMed 2. Seek synergies and align with activities of ongoing EU-AU research programmes and other bi-regional policy actions GADC, EDCTP,.... 3. Contribution to the EU-AU Policy Dialogue and support to the Africa-EU Partnership 	
<p><u>Deliverables</u></p> <ul style="list-style-type: none"> • Action Plan for the involvement of African countries in ICPerMed and ERA PerMed • Report (mid-term) on interactions of EU-Africa PerMed, ICPerMed, ERA PerMed and the Africa-EU Partnership. • Report (final) on interactions of EU-Africa PerMed, ICPerMed, ERA PerMed and the Africa-EU Partnership. 	

WORK PACKAGE 5 M10-M48	CAPACITY BUILDING IN PERSONALISED MEDICINE
<p><u>Objectives:</u></p> <p>To facilitate and increase PM research collaboration between Europe and Africa through training and capacity building actions.</p>	
<p><u>Tasks</u></p> <ul style="list-style-type: none"> • Identification of existing PM training and curriculum development initiatives in Africa • Training Events: Two on-site summer schools, one of them on: Adoption and integration of standards in PM research • Supporting activities and online learning (webinars) 	
<p><u>Deliverables</u></p> <ul style="list-style-type: none"> • Report on existing PM training and curriculum development initiatives in Africa • Report of 1st Summer School • Report of 2nd summer school • Report of on supportive activities and online learning 	

WORK PACKAGE 6 M1-M48	COMMUNICATION AND DISSEMINATION
<p><u>Objectives:</u></p> <ul style="list-style-type: none"> • To raise awareness of the project and outcomes among all relevant stakeholders (e.g. via a newsletter, press releases, twitter, exchange with other initiatives by presenting the project, etc.) • To ensure timely engagement and continuous interactions with relevant stakeholders • To carry out dissemination actions to ensure that relevant stakeholders receive and understand the main findings and results of the project 	
<p><u>Tasks</u></p> <ul style="list-style-type: none"> • Development of the Communication and Dissemination Plan • Elaboration of Communication & Dissemination Material. Flyer, logo, newsletters, press releases, videos, etc. • Design and maintenance of the project website https://www.euafrica-permed.eu/ • Legacy and sustainability of the communication channels beyond the project lifetime 	
<p><u>Deliverables</u></p> <ul style="list-style-type: none"> • Dissemination and Communication Plan • Report I on Dissemination and Communication activities • Report II on Dissemination and Communication activities • Recommendations for communication after project lifetime 	




EU-AFRICA PERMed: EXPECTED RESULTS AND IMPACTS

Short-term

- Facilitate the integration of African organizations in ICPeMed activities
- Support a wider adoption of PM standards developed in Europe to facilitate international collaboration in research projects, for the participation in PM clinical trials, sharing of data and samples.
- Support the EU-AU policy dialogues relevant to research and health

Medium-long term

- Reduce global inequities in PM research that can contribute to better disease prevention, diagnosis and treatment.
- Contribute towards the UN Sustainable Development Goal 3: Ensure healthy lives and promote well-being for all at all ages.



**THANK YOU VERY MUCH
FOR YOUR ATTENTION**



@EU_AfricaPerMed



www.euafrica-permed.eu